Towards Healthcare
Gestational Diabetes Market to Promote USD 22.58 Bn by 2034

Gestational Diabetes Market Future Driven by Smart Monitoring

The gestational diabetes market features comprehensive segmentation and statistical coverage, spanning treatment methods, drug formulations, dosage forms, diagnostics, and end-use industries. It includes global and regional market data, trade analysis, supply chain mapping, and competitive positioning of top companies. Each region’s performance  North America (34% share), Europe, and Asia-Pacific (fastest-growing CAGR)  is detailed with import export patterns, price trends, and supplier dynamics. The market’s expansion from USD 10.3 billion (2025) to USD 22.58 billion (2034) reflect a 9.15% CAGR growing awareness and technological advances.

Content

  • Last Updated: 03 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The gestational diabetes market is worth USD 11.24 billion in 2026, and by 2034, it is forecasted to hit USD 22.58 billion, registering a CAGR of 9.15% over the decade.

North America is leading the gestational diabetes market share by 34% due to the availability of state-of-the-art research and development facilities, the presence of key players, and the increasing adoption of advanced technologies.

Some key players include Eli Lilly and Company, Biocon Limited, and Johnson & Johnson.

Key trends include the rising prevalence of gestational diabetes, advancements in diabetes monitoring technologies, and increasing awareness.

Gestational diabetes can be prevented by focusing on a healthy lifestyle, eating a balanced diet, and exercising regularly for at least 30 minutes a day.

International Diabetes Federation, National Institute of Health, clinicaltrials.gov, NHS England
Any Questions